Leqembi

Amyloid-Beta Structure Revelation Sheds Light on Leqembi’s Function
Amyloid-Beta Structure Revelation Sheds Light on Leqembi’s Function
BioSpace
Eisai
Biogen
Alzheimer's disease
Leqembi
amyloid beta
Flag link:
JAMA: Leqembi could cost Medicare up to $5B per year
JAMA: Leqembi could cost Medicare up to $5B per year
Medical Marketing and Media
Biogen
Eisai
Leqembi
drug pricing
Medicare
Alzheimer's disease
JAMA
Flag link:
Biogen isn’t concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
Biogen isn’t concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
CNBC
Biogen
earnings
Pharma CEOs
Chris Viehbacher
Eli Lilly
Alzheimer's disease
Leqembi
donanemab
Flag link:
Lilly expects US Medicare to reverse course, fully cover Alzheimer's drugs
Lilly expects US Medicare to reverse course, fully cover Alzheimer's drugs
Reuters
Eli Lilly
Medicare
Alzheimer's disease
Leqembi
Flag link:
Despite CMS snub, Eisai is 'not so nervous' about Leqembi's long-term coverage prospects: US CEO
Despite CMS snub, Eisai is 'not so nervous' about Leqembi's long-term coverage prospects: US CEO
Fierce Pharma
Eisai
Leqembi
FDA
CMS
Alzheimer's disease
Flag link:
Alzheimer's Association campaigns for broader Leqembi coverage: report
Alzheimer's Association campaigns for broader Leqembi coverage: report
Fierce Pharma
CMS
Eisai
Biogen
Leqembi
Alzheimer's disease
Flag link:
VA to cover Eisai's new Alzheimer's drug after declining to cover Aduhelm
VA to cover Eisai's new Alzheimer's drug after declining to cover Aduhelm
Endpoints
VHA
Eisai
Biogen
Leqembi
Aduhelm
Alzheimer's disease
Flag link:
Eisai projects $7B in sales by 2030 for new Alzheimer's drug
Eisai projects $7B in sales by 2030 for new Alzheimer's drug
Endpoints
Eisai
Biogen
Alzheimer's disease
Leqembi
Flag link:
FDA sets July decision date for full approval of Leqembi
FDA sets July decision date for full approval of Leqembi
BioSpace
Eisai
Biogen
Alzheimer's disease
Leqembi
FDA
lecanemab
Flag link:
ICER dials up recommended price range for Eisai's Leqembi—but still calls for sizable discount
ICER dials up recommended price range for Eisai's Leqembi—but still calls for sizable discount
Fierce Pharma
ICER
Eisai
Leqembi
drug pricing
Alzheimer's disease
Flag link:
Despite recent approvals, significant unmet need remains in Alzheimer’s market
Despite recent approvals, significant unmet need remains in Alzheimer’s market
Clinical Trials Arena
Alzheimer's disease
Biogen
Eisai
Lundbeck
Otsuka
Avanir Pharmaceuticals
Axesome
Aduhelm
Leqembi
Flag link:
Medicare maintains limits on Eisai’s new Alzheimer’s drug
Medicare maintains limits on Eisai’s new Alzheimer’s drug
BioPharma Dive
Medicare
CMS
Eisai
Biogen
Leqembi
Alzheimer's disease
Flag link:
Eisai Anticipates Full Approval of Leqembi as Early as July
Eisai Anticipates Full Approval of Leqembi as Early as July
BioSpace
Eisai
FDA
Alzheimer's disease
Leqembi
lecanemab
Flag link:
Biogen chairman to step down as new CEO walks thin line with Alzheimer's launch Leqembi
Biogen chairman to step down as new CEO walks thin line with Alzheimer's launch Leqembi
Fierce Pharma
Biogen
Chris Viehbacher
Stelios Papadopoulos
Pharma CEOs
Alzheimer's disease
Leqembi
Flag link:
Eisai gives first glimpse into Alzheimer’s drug launch
Eisai gives first glimpse into Alzheimer’s drug launch
BioPharma Dive
Eisai
Alzheimer's disease
drug launches
Leqembi
Flag link:
Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval
Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval
Motley Fool
Biogen
Eisai
Alzheimer's disease
Leqembi
lecanemab
Flag link:
Alzheimer’s disease trials: How does Lilly’s donanemab compare to lecanemab?
Alzheimer’s disease trials: How does Lilly’s donanemab compare to lecanemab?
Clinical Trials Arena
clinical trials
Alzheimer's disease
Eisai
Biogen
Eli Lilly
Leqembi
lecanemab
donanemab
Flag link:
Eisai learns from Biogen’s Aduhelm disaster
Eisai learns from Biogen’s Aduhelm disaster
EP Vantage
Eisai
Biogen
Leqembi
Aduhelm
Alzheimer's disease
drug pricing
Flag link:
Eisai, in pricing new Alzheimer’s drug, tries to sidestep controversy
Eisai, in pricing new Alzheimer’s drug, tries to sidestep controversy
BioPharma Dive
Eisai
Biogen
drug pricing
Leqembi
Alzheimer's disease
lecanemab
Flag link:
FDA approves Alzheimer’s drug from Eisai, Biogen in closely watched decision
FDA approves Alzheimer’s drug from Eisai, Biogen in closely watched decision
BioPharma Dive
Eisai
Biogen
lecanemab
Leqembi
Alzheimer's disease
FDA
Flag link: